- Home
- TCRX vs HGBL Comparison
TCRX vs HGBL Comparison
Compare TCRX & HGBL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- HGBL
- Stock Information
- Founded
- TCRX 2018
- HGBL 1937
- Country
- TCRX United States
- HGBL United States
- Employees
- TCRX N/A
- HGBL N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- HGBL Business Services
- Sector
- TCRX Health Care
- HGBL Consumer Discretionary
- Exchange
- TCRX Nasdaq
- HGBL Nasdaq
- Market Cap
- TCRX 82.1M
- HGBL 75.5M
- IPO Year
- TCRX 2021
- HGBL N/A
- Fundamental
- Price
- TCRX $1.45
- HGBL $2.23
- Analyst Decision
- TCRX Strong Buy
- HGBL Strong Buy
- Analyst Count
- TCRX 6
- HGBL 1
- Target Price
- TCRX $9.50
- HGBL $4.00
- AVG Volume (30 Days)
- TCRX 669.3K
- HGBL 69.8K
- Earning Date
- TCRX 08-11-2025
- HGBL 08-07-2025
- Dividend Yield
- TCRX N/A
- HGBL N/A
- EPS Growth
- TCRX N/A
- HGBL N/A
- EPS
- TCRX N/A
- HGBL 0.12
- Revenue
- TCRX $4,421,000.00
- HGBL $46,659,000.00
- Revenue This Year
- TCRX $159.20
- HGBL $12.86
- Revenue Next Year
- TCRX N/A
- HGBL $7.02
- P/E Ratio
- TCRX N/A
- HGBL $18.85
- Revenue Growth
- TCRX N/A
- HGBL N/A
- 52 Week Low
- TCRX $1.02
- HGBL $1.52
- 52 Week High
- TCRX $7.89
- HGBL $2.74
- Technical
- Relative Strength Index (RSI)
- TCRX 46.44
- HGBL 62.89
- Support Level
- TCRX $1.39
- HGBL $2.09
- Resistance Level
- TCRX $1.73
- HGBL $2.27
- Average True Range (ATR)
- TCRX 0.15
- HGBL 0.08
- MACD
- TCRX -0.02
- HGBL 0.02
- Stochastic Oscillator
- TCRX 12.53
- HGBL 90.00
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About HGBL Heritage Global Inc.
Heritage Global Inc values and monetizes industrial and financial assets by providing acquisition, disposition, valuation, and lending services for surplus and distressed assets. It aids in facilitating the economy by diverting useful industrial assets from landfills and operating a supply chain by overseeing the post-sale account activity of financial assets. The group operates in four segments namely Auction and Liquidation; Refurbishment and Resale; Brokerage and Specialty Lending. It generates maximum revenue from the Auction and Liquidation segment. The Auction and Liquidation segment, through HGP, operates as a full-service auction, appraisal, and asset advisory firm, including the acquisition of turnkey manufacturing facilities and used industrial machinery and equipment.